Intoplicine is primarily investigated for its potential in cancer therapy due to its ability to inhibit topoisomerase I and II enzymes, which are crucial for DNA replication and cell division. By interfering with these enzymes, it can induce DNA damage in cancer cells, leading to their apoptosis. Its dual inhibition mechanism makes it a promising candidate for treating various cancers, particularly those resistant to single-target topoisomerase inhibitors. Research is ongoing to explore its efficacy in combination with other chemotherapeutic agents and to determine its safety profile in clinical trials.